Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

Medical Oncology

Volumn 23, Issue 4, 2006, Pages 507-513

  Kalmadi, Sujith ^a   McNeill, Giles ^a   Davis, Mellar ^a   Peereboom, David ^a   Adelstein, David ^a   Mekhail, Tarek ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Docetaxel; Gemcitabine; Phase II

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAIL; NEUTROPENIA; PERFORMANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33847000593     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:4:507     Document Type: Article

References (36)

1. Jemal A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
2. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11(10):1866-1872.
3. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106(3):861-865.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000(2):CD002139.
5. Souquet PJ, Chauvin F, Boissel JP, Bernard JP. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer 1995;12(Suppl 1):S147-154.
6. Vansteenkiste JF, et al. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001;12(9):1221-1230.
7. Shepherd FA, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095- 2103.
8. Lynch TJ, Jr. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer. Semin Oncol 2001;28(3 Suppl 9):5-9.
9. Roszkowski K, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27(3):145- 157.
10. Fossella FV, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12): 2354-2362.
11. Hainsworth JD, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19(15):3500-3505.
12. Lilenbaum RC, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001;92(8):2158- 2163.
13. Petrioli R, et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 2003;39(1):85-89.
14. Tsunoda T, et al. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2004;54(2):173-177.
15. Ohe Y, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15(1):45-50.
16. Mekhail T, et al. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer 2003;97(1):170-178.
17. Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999;10(8):943- 947.
18. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland), 1979.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958(53):457-481.
20. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899-909.
21. Georgoulias V, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001;357(9267):1478-1484.
22. Kosmidis P, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20(17):3578-3585.
23. Van Meerbeeck JP, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced NSCLC. In: ASCO 2001.
24. Pfister DG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22(2):330-353.
25. Rizvi NA, et al. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin Oncol 1999;26(5 Suppl 16):27-31; discussion 41-42.
26. Rizvi NA. Docetaxel (Taxotere) and gemcitabine in combination therapy. Semin Oncol 1999;26(3 Suppl 11):19-22.
27. Neubauer MA, et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 2005;47(1):121-127.
28. Spiridonidis CH, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 2001;12(1):89-94.
29. van Oosterom AT. Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies. Semin Oncol 1999;26(3 Suppl 10):8-11.
30. J. R. Rigas MC, B. Cole, A. Evans, R. Page, F. Yunus, M. Ruben, H. Ghazal, K. Dragnev, The Dartmouth Non-Platinum Based Chemotherapy Trial Investigators; Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH. Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112). In: 2004 ASCO annual meeting 2004.
31. Hainsworth JD, Burris HA, 3rd, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28(3 Suppl 9):21-25.
32. Kakolyris S, et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 2001;32(2):179-187.
33. Hejna M, et al. Treatment of patients with advanced non-small cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer 2000;89(3):516-522.
34. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-98.
35. Rosell Rea. ERCC1 mRNA based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer. In: ASCO 40th annual meeting 2005.
36. Sandler Aea. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. In: ASCO annual meeting; 2005; 2005.